Compugen Ltd. (CGEN)
NASDAQ: CGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
CGEN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $203.66M
- P/E (TTM)
- 5.66
- EPS (TTM)
- $0.38
- Dividend yield
- None
- 52-week range
- 1.43 – 3.24
- Day range
- 2.13 – 2.23
- Volume / Avg
- 201.71K / 247.77K
- Beta
- —
- Shares outstanding
- 94.72M
52-week range
CGEN stock today
Shares of Compugen (CGEN) finished lower on Oct 7 at $2.15, a drop of 3.15% or $0.07 per share, versus the S&P 500's 0.22% decline. Shares are 33.6% below their 52-week high of $3.24, set on Apr 24, 2026 and 50.3% above the 52-week low of $1.43, in the middle of the past year's range. CGEN is up 40.5% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 22.2%.
Compugen trades at 5.7x its trailing twelve-month earnings per share of $0.38.
Summary generated from market data by MetaCap's automated system. Methodology
About Compugen
Company profileCompugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Eran Ophir Ph.D.
- Headquarters
- Holon
- Employees
- 75
- IPO year
- 2000
- Website
- cgen.com
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$4.60+113.95%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Compugen peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ALECAlector Inc. | 1.92 | +6.08% | $214.38M | vs CGEN |
| IVVDInvivyd Inc. | 0.7286 | -9.65% | $214.76M | vs CGEN |
| PLXProtalix BioTherapeutics Inc. (DE) | 2.71 | -0.73% | $218.35M | vs CGEN |
| CMPXCompass Therapeutics Inc. | 1.02 | +2.19% | $183.69M | vs CGEN |
| IPSCCentury Therapeutics Inc. | 1.28 | -3.03% | $231.78M | vs CGEN |
| DTILPrecision BioSciences Inc. | 6.25 | +0.81% | $172.51M | vs CGEN |
| IPHAInnate Pharma S.A. ADS | 1.52 | -4.40% | $169.78M | vs CGEN |
| LCTXLineage Cell Therapeutics Inc. | 0.9476 | +1.03% | $239.66M | vs CGEN |
Indexes, lists and sector
Compugen stock FAQ
What is Compugen's stock price today?
CGEN last traded at $2.15 as of Oct 7, 4:00 PM EDT, down 3.15% on the day. Prices are delayed at least 15 minutes.
What is CGEN's P/E ratio?
CGEN trades at a trailing P/E ratio of 5.66.
Who is Compugen's CEO?
Dr. Eran Ophir Ph.D. is the chief executive officer of Compugen Ltd., which has about 75 employees.
What is the CGEN 52-week high?
The 52-week high for CGEN is $3.24 and the 52-week low is $1.43. The stock is currently 33.6% below its high.